TL;DR
This study provides a comprehensive, nationwide look at how newly diagnosed type 2 diabetes patients in China are treated and how their glycemic control evolves over a year. It reveals that while many patients start with diet and exercise alone, treatment patterns shift, and achieving glycemic targets is more likely with oral medications than with insulin, highlighting potential areas for optimizing care.
What Problem Does This Paper Address?
Type 2 diabetes is a growing global health crisis, with China having the largest number of affected individuals. Despite this, there was a significant lack of data on the real-world treatment patterns and clinical outcomes for newly diagnosed type 2 diabetes patients specifically within China. Understanding these initial treatment strategies and their effectiveness is crucial for guiding clinical practice, developing national guidelines, and ultimately improving patient outcomes by attenuating disease progression and reducing complications. This study aims to fill that knowledge gap by tracking a large cohort of newly diagnosed patients over 12 months.
Methods
This was a prospective, observational cohort study conducted across 81 hospitals in China, involving patients diagnosed with type 2 diabetes for less than six months. The study followed 5,770 participants for 12 months, collecting data every three months. Key data points included:
- Demographics and Baseline Characteristics: Age, sex, region, education, medical history, comorbidities (hypertension, dyslipidemia, etc.), health behaviors (smoking, exercise), physical exams, and lab tests (HbA1c, fasting glucose, lipid profile).
- Hypoglycemic Treatment Patterns: Detailed information on diet and exercise, herbal medicine, oral hypoglycemic agents (OHAs – including metformin, sulfonylureas, glinides, alpha-glucosidase inhibitors, thiazolidinediones, and DPP-4 inhibitors), and insulin use.
- Clinical Outcomes: Glycated hemoglobin A1c (HbA1c) levels were the primary measure of glycemic control.
- Treatment Modifications: Changes in antidiabetes treatment (ADT) were tracked, along with patient-reported reasons for these changes.
Statistical analyses included descriptive statistics, ANOVA, and chi-squared tests. A generalized estimating equation (GEE) model was used for multivariate analysis to identify factors associated with glycemic control and treatment alterations.
Datasets
The study utilized data collected from 5,770 newly diagnosed type 2 diabetes patients recruited from 79 hospitals across six geographic regions in China. This represents a novel, nationwide dataset for this specific patient population.
Key Insights and Ideas
- Initial Treatment Diversity: A significant portion of newly diagnosed patients (44.6%) started with just diet and exercise, indicating a conservative initial approach, even with elevated HbA1c levels.
- Treatment Evolution: Over 12 months, there was a notable shift in treatment patterns, with a decrease in patients on diet/exercise alone and an increase in those using OHAs and insulin.
- Oral Agents vs. Insulin for Control: Patients on one OHA were more likely to achieve glycemic control (<7% HbA1c) compared to those not on medication. Conversely, patients using insulin (alone or in combination) had a lower likelihood of reaching the target, suggesting that insulin might be reserved for more severe cases or that its initial use in this cohort was less effective for achieving target control.
- Importance of Follow-up: Regular follow-up visits were strongly associated with improved glycemic control, highlighting the value of consistent patient-physician interaction.
- Comorbidities Matter: The presence of hypertension, and especially hypertension combined with dyslipidemia, was associated with a higher likelihood of achieving glycemic control.
- Lifestyle Factors Influence Control: Obesity and current smoking were linked to a lower chance of achieving glycemic targets.
- Reasons for Change: Poor efficacy and patient's personal choices were the primary drivers for treatment alterations, underscoring the need for patient-centered care and effective drug selection.
Key Results
- HbA1c Improvement: Mean HbA1c decreased from 8.4 ± 2.5% at baseline to 6.7 ± 1.2% at 12 months (P < 0.0001).
- Target Achievement: 68.5% of patients achieved an HbA1c <7.0% by the end of the 12-month follow-up.
- Baseline Treatment Distribution: 44.6% on diet/exercise, 37.7% on OHAs, and 17.7% on insulin.
- 12-Month Treatment Distribution: 23.9% on diet/exercise, 56.5% on OHAs, and 19.6% on insulin.
- One OHA Efficacy: Patients on one OHA had a significantly increased possibility of reaching adequate glycemic control (RR 1.07; P < 0.001) compared to those without medication.
- Insulin Efficacy: Patients on insulin alone (RR 0.93; P = 0.01), insulin + one OHA (RR 0.90; P = 0.003), and insulin + two OHAs (RR 0.85; P = 0.005) had lower possibilities of reaching the target.
- Obesity Impact: Obese patients (BMI ≥28 kg/m²) had a lower possibility of reaching adequate controls (RR 0.96; P = 0.01).
- Smoking Impact: Active smokers tended to have a lower possibility of reaching adequate controls (RR 0.95; P = 0.008).
Limitations and Future Work
The authors acknowledge several limitations:
- No HbA1c Correction: Laboratory test results from various hospitals were used without further correction, though they note that industry standards have improved consistency.
- Short Follow-up Duration: A 12-month follow-up is insufficient to assess long-term clinical outcomes like macrovascular and microvascular complications.
- Uncollected Factors: Information on eating habits, patient professions, and long-term medication safety was not collected.
- Selection Bias: As a real-world observational study, selection bias could not be avoided.
Future work should include longer, multi-year longitudinal cohort studies to provide more comprehensive answers on clinical outcomes and to further explore factors influencing diabetes management.
Summary updated